Truist raised the firm’s price target on Integra LifeSciences to $46 from $44 and keeps a Hold rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences price target raised by $5 at Truist, here’s why
- Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®
- Integra to acquire Acclarent from Johnson & Johnson for $275M
- Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors
- Integra LifeSciences names 3D Systems CEO Jeff Graves to board